(R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide
| Title | Journal |
|---|---|
| International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. | Pharmacological reviews 20140101 |
| Chemokine receptor antagonists. | Journal of medicinal chemistry 20121126 |
| LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. | International immunopharmacology 20120701 |
| Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20120701 |
| The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. | Molecular cancer therapeutics 20120601 |
| Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. | Blood 20111027 |
| Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. | Cancer letters 20110128 |
| A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. | British journal of pharmacology 20100401 |
| SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. | The European respiratory journal 20100301 |
| Neutrophils in chronic inflammatory airway diseases: can we target them and how? | The European respiratory journal 20100301 |
| CXCR2 inverse agonism detected by arrestin redistribution. | Journal of biomolecular screening 20091001 |
| Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region. | Bioorganic & medicinal chemistry letters 20090801 |
| Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090401 |
| Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists. | Bioorganic & medicinal chemistry letters 20080315 |
| Future therapeutic treatment of COPD: struggle between oxidants and cytokines. | International journal of chronic obstructive pulmonary disease 20070901 |
| A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. | The Journal of pharmacology and experimental therapeutics 20070801 |
| Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. | The Journal of pharmacology and experimental therapeutics 20070801 |
| C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20070701 |
| Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. | Journal of medicinal chemistry 20061228 |